INTRACELLULAR PHARMACOKINETICS OF 2-CHLORODEOXYADENOSINE IN LEUKEMIA-CELLS FROM PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA

被引:0
|
作者
ALESSISEVERINI, S
GATI, WP
BELCH, AR
PATERSON, ARP
机构
[1] UNIV ALBERTA, DEPT PHARMACOL, EDMONTON, AB T6G 2H7, CANADA
[2] CROSS CANC INST, DEPT MED, EDMONTON, AB T6G 1Z2, CANADA
关键词
2-CHLORODEOXYADENOSINE (2-CDA); NITROBENZYLTHIOINOSINE (NBMPR); CHRONIC LYMPHOCYTIC LEUKEMIA (CLL); NUCLEOSIDE TRANSPORT INHIBITION; TRANSPORTER-MEDIATED EFFLUX; EFFLUX BLOCKADE;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
2-Chlorodeoxyadenosine (2-CdA) is an important agent in the treatment of hairy cell leukemia and chronic lymphocytic leukemia (CLL). Others have reported that levels of 2-CdA phosphates present in human leukemia cells decline rapidly when the cells are in 2-CdA-free medium (Santana et al. J Clin Oncol 1991; 9: 416-422). In the present study, time-courses of 2-CdA lass from CLL cells were biexponential: the mean half-life of the initial phase was 0.30 +/- 0.18 h; the presence of 0.5 mu M nitrobenzylthioinosine (NBMPR, a classical inhibitor of nucleoside transport) in the suspending medium, significantly decreased the initial rate of 2-CdA efflux (mean half-life, 0.43 +/- 0.22 h). As a consequence, AUCs (areas under time-course plots) were significantly higher in the NBMPR-treated cells (4.56 +/- 2.01 pmol . h/10(6) cells, n = 19) than in untreated control cells (3.83 +/- 1.74 pmol . h/10(6) cells; n = 19). 2-CdA was the principal efflux product released into the medium from 2-CdA-loaded CLL cells. We conclude that nucleoside transport processes contribute to the efflux of 2-CdA from CLL cells and that NBMPR may be useful as a retentive agent.
引用
收藏
页码:1674 / 1679
页数:6
相关论文
共 50 条
  • [31] PHARMACOKINETICS AND METABOLISM OF CHLORAMBUCIL IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA
    MCLEAN, A
    WOODS, R
    CATOVSKY, D
    BRITISH JOURNAL OF CANCER, 1978, 38 (01) : 188 - 188
  • [32] INTRACELLULAR ZINC IN CHRONIC LYMPHOCYTIC-LEUKEMIA
    KANTER, RJ
    RAI, KR
    MUNIZ, F
    MICHAEL, B
    BALKON, J
    SAWITSKY, A
    CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1982, 24 (01): : 26 - 32
  • [33] 2-chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia
    Robak, T
    Blasinska-Morawiec, M
    Blonski, JZ
    Dmoszynska, A
    LEUKEMIA & LYMPHOMA, 1999, 34 (1-2) : 151 - 157
  • [34] 2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger
    T Robak
    JZ Błoński
    H Urbańska-Ryś
    M Błasińska-Morawiec
    AB Skotnicki
    Leukemia, 1999, 13 : 518 - 523
  • [35] 2-chlorodeoxyadenosine (cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger
    Robak, T
    Blonski, JZ
    Urbanska-Rys, H
    Blasinska-Morawiec, M
    Skotnicki, AB
    LEUKEMIA, 1999, 13 (04) : 518 - 523
  • [36] Effectiveness of 2-chlorodeoxyadenosine (2-CDA) in previously untreated patients with chronic lymphocytic leukemia (CLL)
    Komarnicki, M
    Trepinska, E
    Kazmierczak, M
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 445 - 445
  • [37] INDUCTION OF FEATURES CHARACTERISTIC OF HAIRY-CELL LEUKEMIA IN CHRONIC LYMPHOCYTIC-LEUKEMIA AND PROLYMPHOCYTIC LEUKEMIA-CELLS
    ZIEGLERHEITBROCK, HWL
    MUNKER, R
    DORKEN, B
    GAEDICKE, G
    THIEL, E
    CANCER RESEARCH, 1986, 46 (04) : 2172 - 2178
  • [38] Treatment of refractory large granular lymphocytic leukemia with 2-chlorodeoxyadenosine
    Edelman, MJ
    ODonnell, RT
    Meadows, I
    AMERICAN JOURNAL OF HEMATOLOGY, 1997, 54 (04) : 329 - 331
  • [39] INTRACELLULAR LDH ISOENZYMES IN CHRONIC LYMPHOCYTIC-LEUKEMIA
    DAVIS, S
    NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (07): : 425 - 425
  • [40] Myelodysplastic following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA)
    SH Kroft
    MS Tallman
    JM Shaw
    M Thangavelu
    LA Peterson
    Leukemia, 1997, 11 : 170 - 170